Short- and long-term outcomes after large pulmonary resection for germ cell tumors after bleomycin-combination chemotherapy

Ann Thorac Surg. 2004 Oct;78(4):1224-8; discussion 1228-9. doi: 10.1016/j.athoracsur.2004.03.081.

Abstract

Background: Treatment of nonseminomatous germ cell tumors frequently requires bleomycin-combination chemotherapy followed by resection of residual disease. Bleomycin administration however raises concerns with respect to postoperative respiratory complications, particularly for patients undergoing large pulmonary resections. We undertook an institutional review to determine the outcome of large pulmonary resections after bleomycin-combination chemotherapy.

Methods: Between 1981 and 2001, 530 patients presented to our institution for resection of residual intrathoracic disease for either metastatic testicular or primary mediastinal nonseminomatous germ cell tumors. We subsequently reviewed 32 of these patients who required pneumonectomy (n = 19; RIGHT = 9, LEFT = 10) or bilobectomy (n = 13) after bleomycin-combination chemotherapy.

Results: There were four operative deaths (13%). All postoperative deaths occurred in patients undergoing right-sided resections (pneumonectomy, n = 2; bilobectomy, n = 2) as a consequence of pulmonary complications. Operative survivors had a pulmonary morbidity of 18%. Fourteen of 20 long-term survivors were found to have a satisfactory performance status at follow-up.

Conclusions: Otherwise young and healthy male nonseminomatous germ cell tumors patients requiring large pulmonary resections after bleomycin-combination chemotherapy appear to be at higher than anticipated risk for pulmonary-related morbidity and mortality. However long-term survivors report an acceptable functional status.

Publication types

  • Evaluation Study
  • Review

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Bleomycin / adverse effects
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Disease-Free Survival
  • Etoposide / administration & dosage
  • Follow-Up Studies
  • Germinoma / drug therapy
  • Germinoma / secondary*
  • Germinoma / surgery*
  • Humans
  • Life Tables
  • Lung Diseases / chemically induced
  • Lung Diseases / epidemiology
  • Lung Diseases / etiology
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary*
  • Lung Neoplasms / surgery*
  • Male
  • Mediastinal Neoplasms / pathology
  • Pneumonectomy* / methods
  • Pneumonectomy* / mortality
  • Postoperative Complications / epidemiology
  • Postoperative Complications / etiology
  • Respiratory Distress Syndrome / etiology
  • Respiratory Distress Syndrome / mortality
  • Retrospective Studies
  • Survival Analysis
  • Survivors
  • Testicular Neoplasms / pathology
  • Thrombosis / etiology
  • Thrombosis / mortality
  • Time Factors
  • Treatment Outcome

Substances

  • Bleomycin
  • Etoposide
  • Cisplatin